Radu Aricescu is one of four people to join the new scientific advisory board of Confo Therapeutics NV, a Belgian company developing antibody fragments directed at G-protein coupled receptors (GPCRs). Dr Aricescu is a programme leader at the MRC Laboratory of Molecular Biology in Cambridge, UK. His research focuses on synaptic connectivity.
He is joined on the board by Peter Kolb, professor of pharmaceutical chemistry at Philipps-University Marberg, Germany and Graeme Milligan, a professor of molecular pharmacology at the University of Glasgow, UK. Jan Steyaert, founder of Confo, is chairman of the new board. He is scientific director of the VIB-VUB Center for Structural Biology and professor at the Vrije Universiteit Brussel.
Confo Therapeutics announced the appointments on 28 February 2019.
Copyright 2019 Evernow Publishing Ltd